Synthesis of 2,4-Diamino-6-[2‘-O-(ω-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as Potent and Selective Inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium Dihydrofolate Reductase
- 10 April 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (10), 2475-2485
- https://doi.org/10.1021/jm030599o
Abstract
Six previously undescribed N-(2,4-diaminopteridin-6-yl)methyldibenz[b,f]azepines with water-solubilizing O-carboxyalkyloxy or O-carboxybenzyloxy side chains at the 2'-position were synthesized and compared with trimethoprim (TMP) and piritrexim (PTX) as inhibitors of dihydrofolate reductase (DHFR) from Pneumocystis carinii (Pc), Toxoplasma gondii (Tg), and Mycobacterium avium (Ma), three of the opportunistic organisms known to cause significant morbidity and mortality in patients with AIDS and other disorders of the immune system. The ability of the new analogues to inhibit reduction of dihydrofolate to tetrahydrofolate by Pc, Tg, Ma, and rat DHFR was determined, and the selectivity index (SI) was calculated from the ratio IC(50)(rat DHFR)/IC(50)(Pc, Tg, or Ma DHFR). The IC(50) values of the 2'-O-carboxypropyl analogue (10), with SI values in parentheses, were 1.1 nM (1300) against Pc DHFR, 9.9 nM (120) against Tg DHFR, and 2.0 nM (600) against Ma DHFR. The corresponding values for the 2'-O-(4-carboxybenzyloxy) analogue (12) were 1.0 nM (560), 22 nM (21), and 0.75 nM (630). By comparison, the IC(50) and SI values for TMP were Pc, 13 000 nM (14); Tg, 2800 nM (65); and Ma, 300 nM (610). For the prototypical potent but nonselective inhibitors PTX and TMX, respectively, these values were Pc, 13 nM (0.26) and 47 nM (0.17); Tg, 4.3 nM (0.76) and 16 nM (0.50); Ma, 0.61 nM (5.4) and 1.5 nM (5.3). Thus 10 and 12 met the criterion for DHFR inhibitors that combine the high selectivity of TMP with the high potency of PTX and TMX.Keywords
This publication has 34 references indexed in Scilit:
- Structure analysis of human dihydrofolate reductase complexes with trimethoprim and epiroprimActa Crystallographica Section A Foundations of Crystallography, 2002
- The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseThe New England Journal of Medicine, 2001
- How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?Journal of Computational Chemistry, 2000
- Cost Effectiveness of Combination HIV TherapyPharmacoEconomics, 2000
- Incidence and Risk Factors of Toxoplasmosis in a Cohort of Human Immunodeficiency Virus‐Infected Patients: 1988‐1995Clinical Infectious Diseases, 1999
- Synthesis of 2,4-Diaminopteridines with Bulky Lipophilic Groups at the 6-Position as Inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mammalian Dihydrofolate ReductasePteridines, 1997
- A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic MoleculesJournal of the American Chemical Society, 1995
- Trimetrexate with Leucovorin versus Trimethoprim-Sulfamethoxazole for Moderate to Severe Episodes of Pneumocystis carinii Pneumonia in Patients with AIDS: A Prospective, Controlled Multicenter Investigation of the AIDS Clinical Trials Group Protocol 029/031The Journal of Infectious Diseases, 1994
- Synthesis and synthetic utility of 1-acyl-5-(trialkylsilyl)-1,2-dihydropyridines. A synthesis of (.+-.)-elaeokanine AThe Journal of Organic Chemistry, 1990
- Thallium in organic synthesis. XL. Preparation and synthetic utility of diarylthallium trifluoroacetatesThe Journal of Organic Chemistry, 1975